CASKP1: A Drug Target and Potential Biomarker (G10029)

Target Name: CASKP1

NCBI ID: G10029

CASKP1

Other Name(s): CASKP | calcium/calmodulin dependent serine protein kinase pseudogene 1 | Calcium/calmodulin-dependent serine protein kinase (MAGUK family) pseudogene 1

CASKP1: A Drug Target and Potential Biomarker

Caskp1 (Cas-like protein 1) is a gene that encodes a protein that is involved in various cellular processes. The protein is expressed in various tissues and organs, including the brain, heart, and gastrointestinal tract. It is a member of the superfamily of Cas proteins, which are known for their ability to interact with small molecules, such as drugs and toxins. The caspases, including caskp1, are involved in the regulation of cellular processes that are critical for the survival and proper function of the cell.

One of the primary functions of caskp1 is its role in the detoxification of harmful substances that can accumulate in the body. This is accomplished through the ability of caskp1 to interact with and decompose these substances, allowing them to be eliminated from the body. In addition, caskp1 is also involved in the regulation of cellular signaling pathways that are important for the development and maintenance of tissues and organs.

The caskpase family has been implicated in a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. One of the primary goals of research into caskp1 and its associated proteins is to identify potential drug targets and biomarkers for these diseases. In addition, caskp1 has also been studied for its potential use as a therapeutic agent for treating a variety of conditions, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the most promising aspects of caskp1 as a drug target is its ability to interact with a wide range of small molecules, including drugs that are known to be toxic to cancer cells. For example, caskp1 has been shown to interact with the drug camptothecin, which is often used to treat breast cancer. Studies have shown that caskp1 can help to reduce the effectiveness of camptothecin by inhibiting its ability to interact with DNA and causing cells to repair themselves. This suggests that caskp1 may be an effective drug target for breast cancer and could potentially be used as a therapeutic agent in this disease.

In addition to its potential use as a drug target, caskp1 has also been studied as a potential biomarker for a variety of diseases. For example, caskp1 has been shown to be involved in the regulation of cellular processes that are important for the development and maintenance of tissues and organs. This suggests that caskp1 may be an effective biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the challenges in studying caskp1 as a biomarker is its limited expression in certain tissues and the difficulty of detecting its presence in these tissues. In addition, the complexity of the cellular processes that are involved in the regulation of caskp1 activity makes it difficult to understand how changes in these processes may affect the levels of caskp1 in the body. However, research into caskp1 and its associated proteins is ongoing and is likely to provide valuable insights into the regulation of cellular processes and the potential use of caskp1 as a drug target and biomarker.

Protein Name: Calcium/calmodulin Dependent Serine Protein Kinase Pseudogene 1

The "CASKP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CASKP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets